Abstract:Angewandte Chemie International EditionVolume 51, Issue 49 p. 12246-12249 Communication Discovery of Small-Molecule Inhibitors of the TLR1/TLR2 Complex† Dr. Kui Cheng, Dr. Kui Cheng Department of Chemistry and Biochemistry and the BioFrontiers Institute, University of Colorado at Boulder, Boulder, CO 80309 (USA)Search for more papers by this authorDr. Xiaohui Wang, Dr. Xiaohui Wang Department of Chemistry and Biochemistry and the BioFrontiers Institute, University of Colorado at Boulder, Boulder, CO 80309 (USA)Search for more papers by this authorShuting Zhang, Shuting Zhang Department of Chemistry and Biochemistry and the BioFrontiers Institute, University of Colorado at Boulder, Boulder, CO 80309 (USA)Search for more papers by this authorProf. Dr. Hang Yin, Corresponding Author Prof. Dr. Hang Yin [email protected] Department of Chemistry and Biochemistry and the BioFrontiers Institute, University of Colorado at Boulder, Boulder, CO 80309 (USA)Department of Chemistry and Biochemistry and the BioFrontiers Institute, University of Colorado at Boulder, Boulder, CO 80309 (USA)Search for more papers by this author Dr. Kui Cheng, Dr. Kui Cheng Department of Chemistry and Biochemistry and the BioFrontiers Institute, University of Colorado at Boulder, Boulder, CO 80309 (USA)Search for more papers by this authorDr. Xiaohui Wang, Dr. Xiaohui Wang Department of Chemistry and Biochemistry and the BioFrontiers Institute, University of Colorado at Boulder, Boulder, CO 80309 (USA)Search for more papers by this authorShuting Zhang, Shuting Zhang Department of Chemistry and Biochemistry and the BioFrontiers Institute, University of Colorado at Boulder, Boulder, CO 80309 (USA)Search for more papers by this authorProf. Dr. Hang Yin, Corresponding Author Prof. Dr. Hang Yin [email protected] Department of Chemistry and Biochemistry and the BioFrontiers Institute, University of Colorado at Boulder, Boulder, CO 80309 (USA)Department of Chemistry and Biochemistry and the BioFrontiers Institute, University of Colorado at Boulder, Boulder, CO 80309 (USA)Search for more papers by this author First published: 11 September 2012 https://doi.org/10.1002/anie.201204910Citations: 100 † We thank the U.S. National Institutes of Health (DA026950, DA025740s and NS067425) for financial support of this work. The sTLR2 DNA plasmid was kindly provided by Dr. Chiaki Nishitani and Dr. Yoshio Kuroki. Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Graphical Abstract An important regulator of innate immunity, the protein complex of Toll-like receptors 1 and 2 (TLR1/TLR2) provides an attractive target for the treatment of various immune disorders. The novel compound CU-CPT22 can compete with the binding of the specific lipoprotein ligand to TLR1/TLR2 (see picture) with high inhibitory activity and specificity. Repression of downstream signaling from TNF-α and IL-1β was also observed. Citing Literature Supporting Information Detailed facts of importance to specialist readers are published as ”Supporting Information”. Such documents are peer-reviewed, but not copy-edited or typeset. They are made available as submitted by the authors. Filename Description anie_201204910_sm_miscellaneous_information.pdf9.5 MB miscellaneous_information Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article. Volume51, Issue49December 3, 2012Pages 12246-12249 RelatedInformation

Small-molecule inhibitors of the TLR3/dsRNA complex.

Small-Molecule TLR8 Antagonists Via Structure-Based Rational Design.

Comprehensive RNAi-based screening of human and mouse TLR pathways identifies species-specific preferences in signaling protein use.

Pyrimidine Triazole Thioether Derivatives As Toll‐Like Receptor 5 (tlr5)/flagellin Complex Inhibitors

Small-Molecule Modulators of Toll-like Receptors

Novel Small Molecule Inhibitors of TLR7 and TLR9: Mechanism of Action and Efficacy In Vivo

Targeting Toll-Like Receptors With Small Molecule Agents

Computational Discovery and Experimental Confirmation of TLR9 Receptor Antagonist Leads

De novo design of protein minibinder agonists of TLR3

Discovery of Novel Small Molecule Dual Inhibitors Targeting Toll-Like Receptors 7 and 8.

Structural insights into pharmacophore-assisted in silico identification of protein-protein interaction inhibitors for inhibition of human toll-like receptor 4 - myeloid differentiation factor-2 (hTLR4-MD-2) complex

Discovery of Novel Small Molecule Dual Inhibitor Targeting Toll-Like Receptors 7 and 9

Discovery of Small‐Molecule Inhibitors of the TLR1/TLR2 Complex

Small-Molecule Modulators Targeting Toll-like Receptors for Potential Anticancer Therapeutics

Recent progress in the development of Toll-like receptor (TLR) antagonists

Design and Optimisation of a Small-Molecule TLR2/4 Antagonist for Anti-Tumour Therapy.

Discovery of Pyrazolo[1,5-Α]pyrimidine Derivatives Targeting TLR4-TLR4*homodimerization Via AI-powered Next-Generation Screening

Discovery of Pyrazolo[1,5- a ]pyrimidine Derivatives Targeting TLR4−TLR4* Homodimerization via AI-Powered Next-Generation Screening

Specific activation of the TLR1-TLR2 heterodimer by small-molecule agonists

Exploring Species-Specificity in TLR4/MD-2 Inhibition with Amphiphilic Lipid A Mimicking Glycolipids

Cover Picture: Pyrimidine Triazole Thioether Derivatives As Toll‐Like Receptor 5 (tlr5)/flagellin Complex Inhibitors (chemmedchem 8/2016)